US Bancorp
GTHX

US Bancorp’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

US Bancorp’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,736
Closed -$34K – 4304
2022
Q3 		$34K Buy
+2,736
New +$31.3K ﹤0.01% 2762
2022
Q1 		– Sell
-772
Closed -$8K – 4241
2021
Q4 		$8K Sell
772
-412
-35% -$5.25K ﹤0.01% 3521
2021
Q3 		$16K Hold
1,184
– – ﹤0.01% 3251
2021
Q2 		$26K Hold
1,184
– – ﹤0.01% 2996
2021
Q1 		$28K Hold
1,184
– – ﹤0.01% 2880
2020
Q4 		$21K Buy
+1,184
New +$17.7K ﹤0.01% 2898

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

US Bancorp's GTHX Position: Q4 2022 in Review

US Bancorp sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 2,736 shares — an estimated $34K sold.

US Bancorp first reported a position in GTHX in Q4 2020 and held it in 6 quarters. The position peaked at $34K in Q3 2022. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

  • US Bancorp reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • US Bancorp sold 2,736 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $34K.
  • US Bancorp first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
  • US Bancorp's G1 Therapeutics, Inc. Common Stock position peaked at $34K in Q3 2022.
  • 116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on US Bancorp's 13F filing for Q4 2022, filed 13 Feb 2023.